Core Insights - The stock of Boan Biotech (06955) has increased by over 3%, currently trading at 18.88 HKD with a transaction volume of 313 million HKD [1] Group 1: Product Approval - Boan Biotech announced that its self-developed product, Bo You Ping® (Dulaglutide injection), has received approval from the National Medical Products Administration for market launch, aimed at blood sugar control in adult patients with type 2 diabetes [1] - Bo You Ping® is the world's first and currently the only approved biosimilar to Trulicity® (the English brand name), with no other domestic dulaglutide injections having entered the Biologics License Application (BLA) stage in China [1] Group 2: Commercialization and Collaboration - The commercialization of Bo You Ping® in mainland China will be conducted in collaboration with Shanghai Pharmaceuticals Holding Co., Ltd [1] Group 3: Technical Expertise - The development of dulaglutide, as a peptide-Fc fusion protein, involves complex processes, and the biosimilar's pharmaceutical (CMC) development is challenging [1] - The company possesses extensive technical expertise and experience in the CMC field, with an advanced process development platform that effectively controls critical quality attributes [1] - The innovative analytical platform has successfully developed control methods for key quality attributes, overcoming CMC technical challenges and facilitating the early approval of Bo You Ping® [1] Group 4: Clinical Trials - Beyond the Chinese market, Bo You Ping® has also been approved to conduct clinical trials in the United States [1]
港股异动 博安生物(06955)涨超3% 度拉糖肽注射液博优平®在中国获批上市 商业化与上药控股合作开展